Pak C Y
Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas 75390-8885, USA.
Clin Nephrol. 2000 Oct;54(4):271-5.
To ascertain whether hypomagnesemia develops during short-term thiazide treatment in normal subjects and if it can be corrected by potassium-magnesium citrate (Relyte) supplementation.
Serum magnesium data were retrieved from 242 normal subjects from prior 4 trials. After 1-3 weeks of treatment with hydrochlorothiazide 50 mg/day, subjects received supplementation with Relyte or a related compound while continuing on thiazide for 3 weeks.
Hypomagnesemia (< or =1.8 mg/dl) was disclosed in 19.4% of 242 subjects on thiazide alone. In such patients, Relyte treatment significantly increased serum magnesium concentration to the normal range, whereas supplementation with potassium citrate or potassium chloride did not. In the Relyte group comprised of 131 subjects, the frequency of hypomagnesemia decreased from 22.9% on thiazide alone to 4.6% after 4 weeks of Relyte supplementation. In contrast, the frequency of hypomagnesemia displayed a non-significant increase from 15.7% on thiazide alone to 20-24% on potassium citrate or potassium chloride.
Mild hypomagnesemia develops in about one fifth of normal subjects during short-term thiazide treatment. Relyte can readily correct it.
确定正常受试者在短期噻嗪类药物治疗期间是否会发生低镁血症，以及补充枸橼酸钾镁（瑞莱泰）是否可以纠正低镁血症。
从之前4项试验的242名正常受试者中获取血清镁数据。在接受50毫克/天氢氯噻嗪治疗1 - 3周后，受试者在继续服用噻嗪类药物的同时接受瑞莱泰或相关化合物补充剂治疗3周。
仅接受噻嗪类药物治疗的242名受试者中，有19.4%出现低镁血症（≤1.8毫克/分升）。在这些患者中，瑞莱泰治疗可使血清镁浓度显著升高至正常范围，而补充枸橼酸钾或氯化钾则不能。在由131名受试者组成的瑞莱泰组中，低镁血症的发生率从仅使用噻嗪类药物时的22.9%降至补充瑞莱泰4周后的4.6%。相比之下，低镁血症的发生率从仅使用噻嗪类药物时的15.7%无显著增加至使用枸橼酸钾或氯化钾时的20 - 24%。
正常受试者在短期噻嗪类药物治疗期间约五分之一会发生轻度低镁血症。瑞莱泰可以很容易地纠正它。
